UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3687168 (State or Other ...

Catabasis Pharmaceuticals Inc. (CATB) Q4 2019 Earnings Conference Call March 10, 2020 8:30 AM ET Company Participants Andrea Matthews - Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Joanne Donovan - Chief Medical Officer Andrew Komjathy - Chief Commercial Officer Andy Nichols - Chief Scientific Officer Noah Clauser - Vice President, Finance Conference Call Participants Liana Moussatos - Wedbush Securities Hartaj Singh - Oppenheimer Operator Ladies and gentlemen, thank you for standi ...

Use these links to rapidly review the document TABLE OF CONTENTS PART IV Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exac ...

Catabasis Pharmaceuticals Inc. (CATB) Q3 2019 Earnings Conference Call November 7, 2019 8:30 AM ET Company Participants Andrea Matthews – Vice President-Corporate Affairs Jill Milne – Chief Executive Officer Joanne Donovan – Chief Medical Officer Andrew Komjathy – Chief Commercial Officer Andy Nichols – Chief Scientific Officer Noah Clauser – Vice President-Finance Conference Call Participants Joel Beatty – Citi Jackie Yan – Oppenheimer and Company. Operator Ladies and gentlemen, thank you for standing-by a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ...

Catabasis Pharmaceuticals Inc. (CATB) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Jill Milne - Chief Executive Officer Noah Clauser - Vice President, Finance Joanne Donovan - Senior Vice President, Clinical Development, Chief Medical Officer Andrew Nichols - Chief Scientific Officer Andrea Matthews - Vice President, Corporate Affairs Conference Call Participants Hartaj Singh - Oppenheimer Joel Beatty - Citi Operator Good day ladies and gentlemen and welcome to the Q2 201 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3687168 ...